{"doi":"10.1111/iju.15090","title":"Patterns of recurrence in genuine and induced oligometastatic castration‐resistant prostate cancer treated with progressive site‐directed therapy","abstract":"<jats:sec><jats:title>Objectives</jats:title><jats:p>To describe oncological outcomes after progressive site‐directed therapy (PSDT) in genuine and induced oligometasatic (OM)‐castration‐resistant prostate cancer (CRPC).</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Thirty‐seven patients with OM‐CRPC treated with PSDT were retrospectively analyzed, and oncological outcomes and recurrence patterns on whole‐body diffusion‐weighted MRI (WB‐DWI) were evaluated.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Twenty‐two (59%) were classified as genuine OM‐CRPC and 15 (41%) as induced OM‐CRPC. A 50% decline in PSA after PSDT was observed in 21 (95%) genuine OM‐CRPCs and 7 (47%) induced OM‐CRPCs (<jats:italic>p</jats:italic> = 0.0005). At a median observation period of 7.3 months, median PSA progression‐free survival were 10.9 months in the genuine OM‐CRPCs and 4.8 months in the induced OM‐CRPCs (<jats:italic>p</jats:italic> = 0.015). Among the patients who developed PSA progression after PSDT, 11 of 15 in the genuine OM‐CRPCs (73%) and 11 of 14 in the induced OM‐CRPCs (79%) underwent WB‐DWI at PSA progression. The median numbers of newly detected metastases were 2 (range: 1–5) in the genuine OM‐CRPCs and 4 (range: 1–40) in the induced OM‐CRPCs (<jats:italic>p</jats:italic> = 0.049). Only one new metastasis appeared in 5 patients from the genuine OM‐CRPCs (46%) and 1 from the induced OM‐CRPCs (9.1%, <jats:italic>p</jats:italic> = 0.048). In 7 of 9 patients from the genuine OM‐CRPCs (78%) and 7 of 8 patients from the induced OM‐CRPCs (88%) who had bone metastases alone, the newly detected metastasis limited to the bone.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Genuine OM‐CRPC had better oncological outcomes after PSDT than induced OM‐CRPC, and the number of lesions detected at recurrence was limited. Induced OM‐CRPC might be a disseminated condition with micrometastases at OM diagnosis.</jats:p></jats:sec>","journal":"International Journal of Urology","year":2023,"id":641039,"datarank":0.24141568686511508,"base_score":1.6094379124341003,"endowment":1.6094379124341003,"self_citation_contribution":0.24141568686511508,"citation_network_contribution":0.0,"self_endowment_contribution":0.24141568686511508,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":4,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1666400,"name":"Taro Takahara","orcid":null,"position":1,"is_corresponding":false},{"id":1117146,"name":"Yuki Arita","orcid":"0000-0002-5285-0352","position":2,"is_corresponding":false},{"id":1666401,"name":"Kazuma Toda","orcid":null,"position":3,"is_corresponding":false},{"id":1666402,"name":"Koichiro Kimura","orcid":null,"position":4,"is_corresponding":false},{"id":1666403,"name":"Motohiro Fujiwara","orcid":"0000-0001-9454-3345","position":5,"is_corresponding":false},{"id":1253814,"name":"Hajime Tanaka","orcid":"0000-0003-3632-2901","position":6,"is_corresponding":false},{"id":1658703,"name":"Minato Yokoyama","orcid":"0000-0002-0245-8934","position":7,"is_corresponding":false},{"id":1666404,"name":"Yoh Matsuoka","orcid":"0000-0002-2440-5104","position":8,"is_corresponding":false},{"id":1666405,"name":"Ryoichi Yoshimura","orcid":null,"position":9,"is_corresponding":false},{"id":1231586,"name":"Yasuhisa Fujii","orcid":"0000-0002-6761-3229","position":10,"is_corresponding":false},{"id":1374486,"name":"Soichiro Yoshida","orcid":"0009-0001-5100-9545","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Patterns of recurrence in genuine and induced oligometastatic castration‐resistant prostate cancer treated with progressive site‐directed therapy","abstract":"<jats:sec><jats:title>Objectives</jats:title><jats:p>To describe oncological outcomes after progressive site‐directed therapy (PSDT) in genuine and induced oligometasatic (OM)‐castration‐resistant prostate cancer (CRPC).</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Thirty‐seven patients with OM‐CRPC treated with PSDT were retrospectively analyzed, and oncological outcomes and recurrence patterns on whole‐body diffusion‐weighted MRI (WB‐DWI) were evaluated.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Twenty‐two (59%) were classified as genuine OM‐CRPC and 15 (41%) as induced OM‐CRPC. A 50% decline in PSA after PSDT was observed in 21 (95%) genuine OM‐CRPCs and 7 (47%) induced OM‐CRPCs (<jats:italic>p</jats:italic> = 0.0005). At a median observation period of 7.3 months, median PSA progression‐free survival were 10.9 months in the genuine OM‐CRPCs and 4.8 months in the induced OM‐CRPCs (<jats:italic>p</jats:italic> = 0.015). Among the patients who developed PSA progression after PSDT, 11 of 15 in the genuine OM‐CRPCs (73%) and 11 of 14 in the induced OM‐CRPCs (79%) underwent WB‐DWI at PSA progression. The median numbers of newly detected metastases were 2 (range: 1–5) in the genuine OM‐CRPCs and 4 (range: 1–40) in the induced OM‐CRPCs (<jats:italic>p</jats:italic> = 0.049). Only one new metastasis appeared in 5 patients from the genuine OM‐CRPCs (46%) and 1 from the induced OM‐CRPCs (9.1%, <jats:italic>p</jats:italic> = 0.048). In 7 of 9 patients from the genuine OM‐CRPCs (78%) and 7 of 8 patients from the induced OM‐CRPCs (88%) who had bone metastases alone, the newly detected metastasis limited to the bone.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Genuine OM‐CRPC had better oncological outcomes after PSDT than induced OM‐CRPC, and the number of lesions detected at recurrence was limited. Induced OM‐CRPC might be a disseminated condition with micrometastases at OM diagnosis.</jats:p></jats:sec>","is_dataset_classified":null,"base_score":1.6094379124341003,"endowment":1.6094379124341003,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"36314128","pmcid":null,"openalex_id":"https://openalex.org/W4307760047","authors":[],"funders":[{"funder_name":"Japan Society for the Promotion of Science London","grant_id":"","title":null},{"funder_name":"Japan Society for the Promotion of Science London","grant_id":"","title":null}],"total_grants":2,"fwci":0.5442,"citation_percentile":0.66126134,"influential_citations":0,"citation_trend":[{"year":2023,"count":2},{"year":2025,"count":2}],"oa_status":"closed","license":"http://onlinelibrary.wiley.com/termsAndConditions#vor","oa_locations":[{"url":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/iju.15090","host_type":"publisher"},{"url":"https://onlinelibrary.wiley.com/doi/full-xml/10.1111/iju.15090","host_type":"publisher"},{"url":"https://doi.org/10.1111/iju.15090","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/36314128","host_type":"repository"},{"url":"https://teikyo-u.repo.nii.ac.jp/records/2027648","host_type":"repository"}],"fields_of_study":["Prostate Cancer Treatment and Research","Prostate Cancer Diagnosis and Treatment","MRI in cancer diagnosis","Male","Humans","Prostatic Neoplasms, Castration-Resistant","Prostate-Specific Antigen","Retrospective Studies","Progression-Free Survival","Diffusion Magnetic Resonance Imaging"],"mesh_terms":["Progression-Free Survival","Humans","Male","Retrospective Studies","Prostate-Specific Antigen","Diffusion Magnetic Resonance Imaging","Prostatic Neoplasms, Castration-Resistant"],"keywords":["Medicine","Prostate cancer","Bone metastasis","Internal medicine","Urology","Oncology","Metastasis","Cancer","Surgery","Prostatic neoplasms","Radiotherapy","Recurrence","Castration-resistant","Oligometastasis"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-07T15:32:26.087379Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}